

I CHOOSE

PRECISION
IN THE VIAL

PRECISION
IN YOUR HANDS

FOR THE **METICULOUS** ME

"Quality comes first for my patients and me."

The BOTOX® Cosmetic manufacturing process is built on precision to ensure manufacturing quality and safety, vial after vial.[1,2]

FOR THE **CLINICIAN** IN ME

"Evidence guides my decisions."

The makers of BOTOX® Cosmetic developed the clinical scales and injection protocols evaluated in pivotal trials, leading to FDA approval in all 3 indicated areas.[3]

FOR THE **DEPENDABLE** ME

"My patients trust my recommendations."

In a 2018 survey, approximately 8 out of 10 physicians (n = 484) reported they use BOTOX® Cosmetic when injecting a neurotoxin for themselves or a family member.[4]

FOR THE **PREDICTABLE** ME

"I want to know what to expect with the product."

Only BOTOX® Cosmetic offers precise dosing for simultaneous treatment in 3 precise areas across treatment cycles.[3]

FOR THE **RELIABLE** ME

"I want to know I can trust the brand."

BOTOX® Cosmetic is precisely the one patients ask and come back for.[5,6,*]

Actual patients treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. ***Results may vary.***

*92% of patients (n = 142) reported they discussed BOTOX® Cosmetic the first time they were treated. 85% of patients (n = 314) reported they are likely to continue using BOTOX® Cosmetic. Results from online market research surveys. Based on neurotoxin and/or filler patients.[5,6]

BOTOX® Cosmetic (onabotulinumtoxinA) Important Information

Indications

BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:

- Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity
- Moderate to severe lateral canthal lines associated with orbicularis oculi activity
- Moderate to severe forehead lines associated with frontalis activity

IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.

Please see additional Important Safety Information on following pages.

THE PRODUCT IS THE PROCESS AND OUR PROCESS IS BUILT ON PRECISION[1,2]

QUALITY FROM START TO FINISH

DRUG SUBSTANCE MADE FROM A PROPRIETARY CELL BANK[2,7,8]

Our **proprietary process** ensures a consistent and reliable drug substance

METICULOUS FORMULATION AND FILLING[2]

Quality control testing of raw materials, vials sterilized with **injection-grade water**

STERILITY-CONTROLLED FILLING ROOM[2,9]

Air is circulated **200X an hour,** 13X more than in a typical operating room

ADVANCED ASEPTIC PROCESSING[2]

Expert sterile filling operators perform microbial testing **every 4 hours, 24 hours a day**

THOROUGH INSPECTION PROCESSES[2]

100% visual inspection of vials, labels, and cartons, as well as optical character verification

OUR STATE-OF-THE-ART MANUFACTURING IN WESTPORT, IRELAND[2]

CONSISTENT *BOTOX*® COSMETIC UNITS, VIAL AFTER VIAL[2]

Stringent assay testing to assure **100 Units, 100% of the time**

REAL-TIME MONITORING TECHNOLOGY[2]

Maintained within a precise temperature window from our door to yours

100+ MILLION VIALS of *BOTOX*® (onabotulinumtoxinA) and *BOTOX*® COSMETIC DISTRIBUTED GLOBALLY[10,*]

Adhering to **rigorous manufacturing quality and safety** requirements[2]

IMPORTANT SAFETY INFORMATION (continued)
CONTRAINDICATIONS
BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

Please see additional Important Safety Information on following pages.

30+ YEARS† OF EXPERIENCE ENSURING THE QUALITY PRODUCT YOU TRUST[11,12,‡]

*For therapeutic and aesthetic use.
†Over 30 years since the first FDA approval for therapeutic use in 1989.[11]
‡Based on a survey of 381 healthcare providers in which 86% reported they agree the brand has earned their trust (top-2 box on a 6-point scale of agreement).[12]

FOR THE **METICULOUS** ME

"Quality comes first for my patients and me."

BOTOX® COSMETIC onabotulinumtoxinA injection

THE ONE FDA APPROVED FOR SIMULTANEOUS TREATMENT IN 3 AREAS[3]

For temporary improvement in adults in the appearance of **MODERATE TO SEVERE**[3]:

64U total for 3 areas

- **FOREHEAD LINES (FHL)** — **20 Units**
- **GLABELLAR LINES (GL)** — **20 Units**
- **LATERAL CANTHAL LINES (LCL)** — **24 Units**



Actual patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. ***Results may vary.***

RIGOROUSLY STUDIED DOSING AND INJECTION PATTERNS[3]

20U forehead lines: 4 Units in each of 5 injection sites[3]





24U lateral canthal lines: 12 Units per side, 4 Units in each of 3 injection sites (6 total injection points)[3]

20U glabellar lines: 4 Units in each of 5 injection sites[3]

PRECISE CONTROL IN 3 AREAS[3,*]

Approved dosing and injection technique offers precise control for individualized anatomy.

*BOTOX® Cosmetic demonstrated similar results from simultaneous treatment in 3 areas across 3 treatment cycles over the course of a year in the forehead trials. Appropriate treatment areas, dosing, and treatment frequency to be determined by a licensed specialist.[3]

UNPARALLELED CLINICAL INNOVATION[3]

Developed the clinical scales and injection protocols to establish 3 first-of-their-kind aesthetic indications

MOST-STUDIED NEUROTOXIN[13]

Over 4300 publications featuring BOTOX® (onabotulinumtoxinA) and/or BOTOX® Cosmetic*

MORE FDA APPROVALS THAN ANY OTHER NEUROTOXIN[3,11,14-16]:

3 BOTOX® Cosmetic aesthetic uses

11 BOTOX® therapeutic uses

*For therapeutic and aesthetic use.

Achieve desired outcomes with approved dosing.
Results seen in the forehead line trials were achieved using 64 Units in 3 areas (20 Units FHL + 24 Units LCL + 20 Units GL)[3]

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS
Lack of Interchangeability Between Botulinum Toxin Products
The potency units of BOTOX® Cosmetic are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of BOTOX® Cosmetic cannot be compared to nor converted into units of any other botulinum toxin products assessed with any other specific assay method.

Please see additional Important Safety Information on following pages.

FOR THE **CLINICIAN** IN ME

"The evidence guides my decisions."

BOTOX® COSMETIC onabotulinumtoxinA injection

REPEATABLE RESULTS IN SIMULTANEOUS TREATMENT[3]

FOREHEAD LINES PRIMARY END POINT AT 30 DAYS[3]

Composite investigator and subject assessment of forehead line severity at maximum eyebrow elevation at day 30—responder rates (percentage and number of subjects achieving ≥ 2-grade improvement from baseline)

	STUDY 1[3]	STUDY 2[3]
BOTOX® Cosmetic (20U FHL + 20U GL)	61% (178/290)	46% (145/318)
BOTOX® Cosmetic (20U FHL + 24U LCL + 20U GL)	—	53% (166/313)
Placebo	0% (0/101)	1% (1/156)

FHL: forehead lines **LCL:** lateral canthal lines **GL:** glabellar lines

Two pivotal, multicenter, randomized, double-blind, placebo-controlled studies with 1178 patients (921 received BOTOX® Cosmetic) treated for moderate to severe forehead lines and glabellar lines or moderate to severe forehead lines, lateral canthal lines, and glabellar lines simultaneously. The primary end point was investigator and patient assessment of forehead line severity at maximum eyebrow elevation using the 4-point Facial Wrinkle Scale with Photonumeric Guide (FWS) at day 30 following the first treatment.[3]

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)
Spread of Toxin Effect
Please refer to Boxed Warning for Distant Spread of Toxin Effect.

No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines) have been reported. Patients or caregivers should be advised to seek immediate medical care if swallowing, speech, or respiratory disorders occur.

Please see additional Important Safety Information on following pages.

SECONDARY EFFICACY END POINT[3]

Investigator-assessed achievement of none or mild forehead lines from baseline on FWS at maximum eyebrow elevation (treatment success).

STUDY 1[3]

- BOTOX® Cosmetic 40 Units (20U FHL + 20U GL)
- Placebo



STUDY 2[3]

- BOTOX® Cosmetic 64 Units (20U FHL + 24U LCL + 20U GL)
- BOTOX® Cosmetic 40 Units (20U FHL + 20U GL)
- Placebo



BOTOX® COSMETIC onabotulinumtoxinA injection

SIMILAR RESULTS ACROSS CYCLES WITH SIMULTANEOUS TREATMENT[3,17,18]

FOREHEAD LINE TRIALS

Responders achieving ≥ 2-grade composite improvement from baseline on investigator and subject FWS ratings of forehead line severity at maximum eyebrow elevation at day 30.[18]

A total of 165 and 197 patients received 3 cycles of BOTOX® Cosmetic over 1 year 40 Units (20U FHL with 20U GL) and 64 Units (20U FHL, 24U LCL, and 20U GL), respectively.[3]

Patients may begin to see results in **24 TO 48 HOURS** in glabellar lines.[3]

RESPONSE WITH REPEAT TREATMENT: STUDY 1 (2 AREAS)[18]

- BOTOX® Cosmetic 40 Units (20U FHL + 20U GL)
- Placebo (cycle 1); BOTOX® Cosmetic 40 Units (20U FHL + 20U GL; cycles 2 and 3)



FHL: forehead lines **LCL:** lateral canthal lines **GL:** glabellar lines

RESPONSE WITH REPEAT TREATMENT: STUDY 2 (3 AREAS)[5]

- BOTOX® Cosmetic 64 Units (20U FHL + 24U LCL + 20U GL)
- BOTOX® Cosmetic 40 Units (20U FHL + 20U GL; cycle 1) and 64 Units (20U FHL + 24U LCL + 20U GL; cycles 2 and 3)
- Placebo (cycle 1); BOTOX® Cosmetic 64 Units (20U FHL + 24U LCL + 20U GL; cycles 2 and 3)



IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)
Serious Adverse Reactions With Unapproved Use
Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX® injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX® to the site of injection and/or adjacent structures. In several of the cases, patients had pre-existing dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX®. The safety and effectiveness of BOTOX® for unapproved uses have not been established.

Please see additional Important Safety Information on following pages.

Muscles are interrelated[19,20]**:**
Assess every patient in all 3 indicated areas, every time

FOR THE
PREDICTABLE ME

"I want to know what to expect with the product."

BOTOX® COSMETIC onabotulinumtoxinA injection

GIVE THEM PREDICTABLE RESULTS[3]

SUBTLE RESULTS IN FOREHEAD LINES

Before

After (Day 30)

Actual patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.

Photos taken at maximum eyebrow elevation before and after treatment with BOTOX® Cosmetic (onabotulinumtoxinA) at day 30. In clinical trials at day 30, 61% (178/290) and 46% (145/318) of patients demonstrated a ≥ 2-grade improvement from baseline in forehead line severity at maximum eyebrow elevation as compared to 0% (0/101) and 1% (1/156) in placebo, as assessed by both investigators and subjects.[3]

NOTICEABLE RESULTS IN LATERAL CANTHAL LINES

Before

After (Day 30)

Actual patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.

Photos taken at maximum smile before and after treatment with BOTOX® Cosmetic at day 30. In clinical trials at day 30, 26.1% (58/222) and 20.3% (62/306) of patients demonstrated a ≥ 2-grade improvement from baseline in lateral canthal line severity at maximum smile as compared to 1.3% (3/223) and 0% (0/306) in placebo, as assessed by both investigators and subjects.[3]

REAL RESULTS IN GLABELLAR LINES

Before

After (Day 30)

Actual patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.

Photos taken at maximum frown before and after treatment with BOTOX® Cosmetic at day 30. In clinical trials at day 30 as assessed by investigators, 80% (325/405) of patients demonstrated none or mild glabellar line severity at maximum frown as compared to 3% (4/132) in placebo. In clinical trials at day 30 as evaluated by patients, 89% (362/405) of patients achieved at least a moderate improvement in their glabellar line appearance compared to 7% (9/132) in placebo.[3]

7-DAY RESULTS

Before

After (Day 7)

Actual patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.

Photos taken at maximum frown before and after treatment with BOTOX® Cosmetic at day 7. In clinical trials at day 7 as assessed by investigators, 74% (299/405) of patients demonstrated none or mild glabellar line severity at maximum frown as compared to 6% (8/132) in placebo. In clinical trials at day 7 as evaluated by patients, 82% (334/405) of patients achieved at least a moderate improvement in their glabellar line appearance compared to 9% (12/132) in placebo.[3]

PROVEN, 4-MONTH RESULTS

Before



After (Month 4)

Actual patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.

Photos taken at maximum frown before and after treatment with BOTOX® Cosmetic at day 120. In clinical trials at day 120 as assessed by investigators, 25% (102/403) of patients demonstrated none or mild glabellar line severity at maximum frown as compared to 2% (2/128) in placebo. In clinical trials at day 120 as evaluated by patients, 39% (157/403) of patients achieved at least a moderate improvement in their glabellar line appearance compared to 1% (1/128) in placebo.[3]

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Hypersensitivity Reactions

Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such reactions occur, further injection of BOTOX® Cosmetic should be discontinued and appropriate medical therapy immediately instituted. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.

Please see additional Important Safety Information on following pages.

GIVE THEM PREDICTABLE RESULTS[3]

SUBTLE RESULTS IN FOREHEAD LINES

Before

After (Day 30)

Actual patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.

Photos taken at maximum eyebrow elevation before and after treatment with BOTOX® Cosmetic (onabotulinumtoxinA) at day 30. In clinical trials at day 30, 61% (178/290) and 46% (145/318) of patients demonstrated a ≥ 2-grade improvement from baseline in forehead line severity at maximum eyebrow elevation as compared to 0% (0/101) and 1% (1/156) in placebo, as assessed by both investigators and subjects.[3]

NOTICEABLE RESULTS IN LATERAL CANTHAL LINES

Before

After (Day 30)

Actual patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.

Photos taken at maximum smile before and after treatment with BOTOX® Cosmetic at day 30. In clinical trials at day 30, 26.1% (58/222) and 20.3% (62/306) of patients demonstrated a ≥ 2-grade improvement from baseline in lateral canthal line severity at maximum smile as compared to 1.3% (3/223) and 0% (0/306) in placebo, as assessed by both investigators and subjects.[3]

REAL RESULTS IN GLABELLAR LINES

Before

After (Day 30)

Actual patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.

Photos taken at maximum frown before and after treatment with BOTOX® Cosmetic at day 30. In clinical trials at day 30 as assessed by investigators, 80% (325/405) of patients demonstrated none or mild glabellar line severity at maximum frown as compared to 3% (4/132) in placebo. In clinical trials at day 30 as evaluated by patients, 89% (362/405) of patients achieved at least a moderate improvement in their glabellar line appearance compared to 7% (9/132) in placebo.[3]

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)

Cardiovascular System
There have been reports following administration of BOTOX® of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction,

SUBTLE RESULTS IN FOREHEAD LINES

Before

After (Day 30)

Actual patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.

Photos taken at maximum eyebrow elevation before and after treatment with BOTOX® Cosmetic at day 30. In clinical trials at day 30, 61% (178/290) and 46% (145/318) of patients demonstrated a ≥ 2-grade improvement from baseline in forehead line severity at maximum eyebrow elevation as compared to 0% (0/101) and 1% (1/156) in placebo, as assessed by both investigators and subjects.[3]

NOTICEABLE RESULTS IN LATERAL CANTHAL LINES

Before

After (Day 30)

Actual patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.

Photos taken at maximum smile before and after treatment with BOTOX® Cosmetic at day 30. In clinical trials at day 30, 26.1% (58/222) and 20.3% (62/306) of patients demonstrated a ≥ 2-grade improvement from baseline in lateral canthal line severity at maximum smile as compared to 1.3% (3/223) and 0% (0/306) in placebo, as assessed by both investigators and subjects.[3]

REAL RESULTS IN GLABELLAR LINES

Before

After (Day 30)

Actual patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.

Photos taken at maximum frown before and after treatment with BOTOX® Cosmetic at day 30. In clinical trials at day 30 as assessed by investigators, 80% (325/405) of patients demonstrated none or mild glabellar line severity at maximum frown as compared to 3% (4/132) in placebo. In clinical trials at day 30 as evaluated by patients, 89% (362/405) of patients achieved at least a moderate improvement in their glabellar line appearance compared to 7% (9/132) in placebo.[3]

some with fatal outcomes. Some of these patients had risk factors including pre-existing cardiovascular disease. Use caution when administering to patients with pre-existing cardiovascular disease.

Please see additional Important Safety Information on following pages.

GENUINE PATIENT SATISFACTION IN SIMULTANEOUS TREATMENT[3,21]

2-AREA TREATMENT IN FOREHEAD LINE TRIALS[3]

90% of subjects in Study 1 reported being "Mostly Satisfied" or "Very Satisfied" with BOTOX® Cosmetic (onabotulinumtoxinA) compared to 1% with placebo.

82% of subjects in Study 2 reported being "Mostly Satisfied" or "Very Satisfied" with BOTOX® Cosmetic compared to 3% with placebo.

Actual patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. ***Results may vary.***

FACIAL LINE SATISFACTION QUESTIONNAIRE (FLSQ) RESPONSE FREQUENCY AT DAY 60 (% of patients)[3]

		Very satisfied	Mostly satisfied	Neither dissatisfied nor satisfied	Mostly dissatisfied	Very dissatisfied
Study 1: FHL + GL						
FHL	BOTOX® Cosmetic (20U FHL + 20U GL) N = 289	57%	**90%**	33%	4%	4%	2%
FHL	Placebo N = 99	1%	0%	22%	21%	56%
Study 2: FHL + GL						
GL	BOTOX® Cosmetic (20U FHL + 20U GL) N = 317	35%	**82%**	47%	9%	7%	2%
GL	Placebo N = 155	0%	3%	23%	20%	54%

FHL: forehead lines LCL: lateral canthal lines GL: glabellar lines

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)
Increased Risk of Clinically Significant Effects With Pre-existing Neuromuscular Disorders
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from onabotulinumtoxinA (see *Warnings and Precautions*).

3-AREA TREATMENT IN FOREHEAD LINE TRIALS[5]

88% of subjects in Study 2 reported being "Mostly Satisfied" or "Very Satisfied" with BOTOX® Cosmetic 64 Units (20U FHL + 24U LCL + 20U GL) treatment compared to 3% with placebo.[21]

FACIAL LINE SATISFACTION QUESTIONNAIRE (FLSQ) RESPONSE FREQUENCY AT DAY 60 (% of patients)[21]

		Very satisfied	Mostly satisfied	Neither dissatisfied nor satisfied	Mostly dissatisfied	Very dissatisfied
Study 2: FHL + LCL + GL						
FHL, LCL, GL	**BOTOX® Cosmetic** (20U FHL + 24U LCL + 20U GL) n = 313	40.6%	47.3% (**87.9%**)	7%	4.2%	1%
FHL, LCL, GL	Placebo n = 156	3.2%	0%	23.1%	19.2%	53.2%

FHL: forehead lines LCL: lateral canthal lines GL: glabellar lines

Please see additional Important Safety Information on following pages.

FOR THE **RELIABLE** ME

"I want to know I can trust the brand."

BOTOX® COSMETIC onabotulinumtoxinA injection

A PARTNER WHO DRIVES CONSUMER DEMAND

There are an estimated **34.4 MILLION** prospective patients considering a facial injectable.[22,*,†] Allergan Aesthetics invests millions annually to grow the BOTOX® Cosmetic market and get patients into the office to ask about treatment.

13 BILLION PR IMPRESSIONS[23]

BOTOX® Cosmetic is #1 in consumer awareness among neurotoxin brands. We continue to drive awareness with a 360° approach to consumer marketing.

#1-SELLING NEUROTOXIN[24]

In 2019 there were:

~1.4 MILLION unique visits to BotoxCosmetic.com[25]

145,000 gift cards sold[26]

*Estimate calculated by applying the percentage of market survey respondents (US women and men, aged 18 to 75 with a total household income of $50K+) who expressed favorable consideration of an aesthetic treatment against US Census Bureau data.[23]

†Estimate based on survey respondents who would consider a treatment with facial injectables in the next 2 years.[23]

‡Aided and unaided awareness, based on a self-completed online interview with 531 women and men aged 18 to 75 who have used a neurotoxin and/or filler in the past 2 years.[23]



The BOTOX® Cosmetic ***Own Your Look*** campaign, featured during primetime programming on major television networks.[27]

A PARTNER WHO PATIENTS KNOW[28,‡]

Allē

Celebrating **6.4 MILLION MEMBERS**[29]—Allē is the new and improved loyalty program by Allergan Aesthetics. This next-generation program offers practices access to reporting tools and creative marketing materials.

500,000+ FOLLOWERS ON SOCIAL

BOTOX® Cosmetic keeps today's consumers engaged and helps increase demand through social media outreach. As of September 2020, the total impressions were:

46,572,987[30]

131,883,790[30]

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Dysphagia and Breathing Difficulties

Treatment with BOTOX® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (see *Boxed Warning*).

Please see additional Important Safety Information on following pages.

THE ONE[5] FOR NEW PATIENTS

#1 neurotoxin received by first-time patients (89%; n = 531)[§]

THE ONE[5] THEY ASK FOR

BOTOX® Cosmetic is the most requested neurotoxin by patients (92%; n = 142)[§]

THE ONE[6] THEY COME BACK FOR

Majority of patients (85%; n = 314) are likely to continue using BOTOX® Cosmetic[§]

§Results from online market research surveys. Based on neurotoxin and/or filler patients.[5,6]

BOTOX® COSMETIC onabotulinumtoxinA injection

PARTNER IN SUPPORT

A PARTNER WHO SUPPORTS THE PRACTICE AND THE PLANET

Allergan Medical Institute
Advancing Excellence in **Facial Aesthetics**

World-class continuum of hands-on or virtual learning programs responsible for training multiple injectors.

Allergan Partner Privileges (APP)

Your virtual partner, offering a range of rebates and discounts for your practice—the more products you buy, the greater the rebates.

BrandBox

Provides first-in-class educational materials, promotions, and social media posts to help you engage with your patients, featuring **700** assets available for download today.

THE ONE YOU CHOOSE

Approximately **8 OUT OF 10** physicians (n = 484) reported they use BOTOX® Cosmetic when injecting a neurotoxin for themselves or a family member.[4]

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)
Pre-existing Conditions at the Injection Site
Caution should be used when BOTOX® Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s).

Dry Eye in Patients Treated With BOTOX® Cosmetic
There have been reports of dry eye associated with BOTOX® Cosmetic injection in or near the orbicularis oculi muscle. If symptoms of dry eye (eg, eye irritation, photophobia, or visual changes) persist, consider referring patients to an ophthalmologist.

Human Albumin and Transmission of Viral Diseases
This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

ADVERSE REACTIONS
The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for glabellar lines were eyelid ptosis (3%), facial pain (1%), facial paresis (1%), and muscular weakness (1%).

The most frequently reported adverse reaction following injection of BOTOX® Cosmetic for lateral canthal lines was eyelid edema (1%).

The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for forehead lines with glabellar lines were headache (9%), brow ptosis (2%), and eyelid ptosis (2%).

Please see additional Important Safety Information on following page.

DOING OUR PART
FOR A MORE SUSTAINABLE WORLD

Allergan Aesthetics achieves environmental benchmarks in BOTOX® Cosmetic manufacturing[2]:

- **100% renewable electric energy***
- **Zero air emissions**†
- **Zero waste to landfill**‡

BOTOX® Cosmetic NEW shipper gets greener, saving an estimated million pounds of foam from landfills over the next 3 years.

Launching in 2021

- **Thermo-efficient and lightweight** insulation made from clean, recycled cellulose (as opposed to foam)[31]
- **Biodegradable** cellulose container can be converted again to pulp and decomposes within 90 days[31]
- **100% curbside recyclable shipper and outer box** made from recycled paper, wood, and corrugate[31]

*Since 2015.
†No significant emissions to air.
‡Since 2013.

abbvie FOUNDATION

EQUALITY, DIVERSITY, AND INCLUSION

The AbbVie Foundation will donate $50 million as part of a larger initiative to help remedy racial inequality in the USA.[32]

The AbbVie Foundation is a nonprofit 501(c)(3) and focuses its giving on Health and Human Services (HHS) programs. Since its inception in 2013, the AbbVie Foundation has[33]:

- Served over 18 million people
- Volunteered over 334,000 hours by AbbVie employees globally
- Supported 60 partner organizations
- Impacted 90 countries through our programs

BOTOX® COSMETIC
onabotulinumtoxinA
injection

LET PRECISION BE YOUR DECISION

BOTOX® COSMETIC onabotulinumtoxinA injection

PRECISE PROCESS[2]

Accountability, quality, and state-of-the-art manufacturing, from start to finish.

PRECISE SCIENCE[3,11,13-16]

More publications, indications, and clinical research innovation than any other neurotoxin.

PRECISE DOSING, REPEATABLE RESULTS[5]

Know what to expect, including simultaneous and repeat treatments.

PARTNERSHIP

A partner who supports practices, patients, and the planet.

IMPORTANT SAFETY INFORMATION (continued)

DRUG INTERACTIONS

Co-administration of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of BOTOX® Cosmetic may potentiate systemic anticholinergic effects.

The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX® Cosmetic.

USE IN SPECIFIC POPULATIONS

There are no studies or adequate data from postmarketing surveillance on the developmental risk associated with use of BOTOX® Cosmetic in pregnant women. There are no data on the presence of BOTOX® Cosmetic in human or animal milk, the effects on the breastfed child, or the effects on milk production.

For more information on BOTOX® Cosmetic, please see accompanying full Prescribing Information including Boxed Warning and Medication Guide.

REFERENCES: 1. Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. *Biologics*. 2014;8:227-241. **2.** Data on file, Allergan, October 16, 2020; Westport Manufacturing Process. **3.** BOTOX® Cosmetic Prescribing Information, July 2020. **4.** Data on file, Allergan, July 2018; BOTOX® Cosmetic Module (UN11). **5.** Data on file, Allergan, March 27, 2020; Neurotoxin Consumer ATU – Final Report. **6.** Data on file, Allergan, 2016; Facial Injectables Neurotoxins Consumer A&U Tracker. **7.** Samizadeh S, De Boulle K. Botulinum neurotoxin formulations: overcoming the confusion. *Clin Cosmet Investig Dermatol*. 2018;11:273-287. **8.** Pickett A. Botulinum toxin as a clinical product: manufacture and pharmacology. In: Foster KA, ed. *Clinical Applications of Botulinum Neurotoxin*. New York, NY: Springer+BusinessMedia; 2014:7-49. *Current Topics in Neurotoxicity*; vol 5. **9.** Occupational Safety & Health Administration (OSHA), US Department of Labor. Surgical Suite. OSHA website. https://www.osha.gov/SLTC/etools/hospital/surgical/surgical.html. Accessed October 21, 2020. **10.** Data on file, Allergan, February 21, 2019; Number of Total Vials Produced at Westport. **11.** BOTOX® Prescribing Information, September 2020. **12.** Data on file, Allergan, April 2018; Facial Injectable MD Landscape Study. **13.** Data on file, Allergan, 2019; Botulinum Toxin Peer-Reviewed Publications. **14.** *Dysport*® Prescribing Information, July 2020. **15.** *Xeomin*® Prescribing Information, August 2020. **16.** *Jeuveau*® Prescribing Information, January 2020. **17.** Data on file, Allergan, September 19, 2016; Clinical Study Report. **18.** Data on file, Allergan, September 15, 2016; Clinical Study Report. **19.** Michaud T, Gassia V, Belhaouari L. Facial dynamics and emotional expressions in facial aging treatments. *J Cos Derm*. 2015;4:9-21. **20.** Benedetto AV, ed. *Botulinum Toxin in Clinical Dermatology*. Oxfordshire, UK: Taylor & Francis; 2006. **21.** Data on file, Allergan, 2016; Clinical Study Report Satisfaction Table. **22.** Data on file, Allergan, May 20, 2020; Sizing Allergan Facial Injectable Opportunities. **23.** Data on file, Allergan, October 11, 2019; PR Results Reported by Lippe Taylor. **24.** Data on file, Allergan, May 2020; Neurotoxin Monthly Tracker Report. **25.** Data on file, Allergan, September 17, 2020; FCB Analytics. **26.** Data on file, Allergan, 2019; BOTOX® Cosmetic Consumer Campaign. **27.** Data on file, Allergan, September 17, 2020; BOTOX® Cosmetic Media Placements. **28.** Data on file, Allergan, April 12, 2019; Neurotoxin Facial Injectables Consumer ATU Final Report. **29.** Data on file, Allergan, 2020; Brilliant Distinctions® US Database. **30.** Data on file, Allergan, September 17, 2020; BOTOX® Cosmetic Social Consumer Statistics. **31.** Data on file, Allergan, 2020; Shipper Box Manufacturing Memo. **32.** Data on file, Allergan, 2020; Our Principles. **33.** AbbVie Foundation. Responsibility: Dedicated to serving unmet needs across the globe. AbbVie website. https://www.abbvie.com/responsibility/abbvie-foundation.html. Published 2020. Accessed October 21, 2020.

Allergan Aesthetics
an AbbVie company

 hcp.BotoxCosmetic.com 1-800-BOTOXMD BCT141130-v3 11/20 004816